Sanofi | SNY - Sales Revenues




Sanofi reported EUR14.76B in Sales Revenues for its fiscal quarter ending in September of 2024.

Sales Change Date
AbbVie USD 15.1B 640M Dec/2024
Amgen USD 9.1B 600M Dec/2024
AstraZeneca USD 14.89B 1.32B Dec/2024
Bristol-Myers Squibb USD 12.34B 440M Dec/2024
Canopy Growth CAD 62.99M 3.22M Sep/2024
Corcept Therapeutics USD 182.5M 18.7M Sep/2024
Drreddys Laboratories INR 80.16B 3.44B Sep/2024
Eli Lilly USD 13.53B 2.09B Dec/2024
Galapagos EUR 75.85M 16M Dec/2024
Genmab DKK 64.41B 58.87B Dec/2024
GlaxoSmithKline GBP 8.12B 108M Dec/2024
Glaxosmithkline GBP 8.01B 128M Sep/2024
Indivior 307M 8M Sep/2024
J&J USD 22.52B 20M Dec/2024
Merck USD 15.6B 1.06B Dec/2024
Novartis USD 13.15B 330M Dec/2024
Novartis USD 13.17B 300M Sep/2024
Pacira USD 168.57M 9.43M Sep/2024
Perrigo USD 1.09B 12.5M Sep/2024
Pfizer USD 17.8B 100M Dec/2024
Prestige Brands USD 290.3M 6.51M Dec/2024
Roche Holding CHF 31.64B 883M Dec/2024
Sanofi EUR 10.56B 2.88B Dec/2024
Sanofi EUR 14.76B 3.19B Sep/2024
Supernus Pharmaceuticals USD 175.69M 7.36M Sep/2024
UCB EUR 2.79B 127M Jun/2024
Zoetis USD 2.32B 80M Dec/2024